Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
Authors:
- Issei SaekiISIssei Saeki
- Takahiro YamasakiTakahiro Yamasaki
- Yurika YamauchiYYYurika Yamauchi
- Taro TakamiTTTaro Takami
- Tomokazu KawaokaTomokazu Kawaoka
- Shinsuke UchikawaSUShinsuke Uchikawa
- Akira HiramatsuAHAkira Hiramatsu
- Hiroshi AikataHAHiroshi Aikata
- Reo KawanoRKReo Kawano
- Kazufumi KobayashiKKKazufumi Kobayashi
- Takayuki KondoTKTakayuki Kondo
- Sadahisa OgasawaraSOSadahisa Ogasawara
Open Access
Abstract
Few studies exist on the relationship between post-progression survival (PPS) and skeletal muscle volume in hepatocellular carcinoma (HCC) patients receiving sorafenib. This study aimed to analyze the effects of muscle volume on clinical outcomes. We retrospectively enrolled 356 HCC patients. Various clinical parameters, including skeletal muscle index, were analyzed as predictors of overall survival (OS), progression-free survival (PFS), and PPS. Patients with high muscle volume showed longer survival or PPS than those with low muscle volume (median survival time: 12.8 vs. 9.5 months, p = 0.005; median PPS: 8.2 vs. 6.3 months, p = 0.015); however, no differences in PFS were found. Multivariate analysis indicated that muscle volume was an independent predictor of PPS and OS. Skeletal muscle volume was a PPS predictor in HCC patients receiving sorafenib. Therefore, survival can be prolonged by the upregulation of skeletal muscle volume, especially in HCC patients with skeletal muscle depletion.Keywords
This publication has 46 references indexed in Scilit:
- Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinomaJournal of Hepatology, 2015
- Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2013
- Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenibHepatology Research, 2013
- Postprogression survival for first-line chemotherapy in patients with advanced gastric cancerEuropean Journal of Cancer, 2013
- Effect of treatment with branched‐chain amino acids during sorafenib therapy for unresectable hepatocellular carcinomaHepatology Research, 2013
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerAnnals of Oncology, 2011
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical TrialsJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008